Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26708754 | 0.88 | MEN1 (0.49) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL17948452 | 0.86 | GABRP (0.51) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL19029728 | 0.85 | POLB (0.51) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL8399451 | 0.85 | POLB (0.51) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL26708752 | 0.83 | POLB (0.44) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL8398543 | 0.82 | POLB (0.49) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL26930705 | 0.82 | POLB (0.58) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL8396849 | 0.82 | LMNA (0.65) | POLBTHRBMAPTLMNAALDH1A1 | |
| SCHEMBL27545443 | 0.82 | THRB (0.52) | POLBMEN1KMT2ATHRBMAPT | |
| SCHEMBL8397035 | 0.81 | MEN1 (0.62) | POLBMEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119343346-A | Benzenesulfonamide derivative, process for preparing the same, and pharmaceutical composition for preventing or treating cancer containing the same as active ingredient | 韩国化学研究院 | 2025-01-21 | — | — | CN | disclosed |
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9718821-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2817308-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2942346-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| CN-104271576-A | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC | 2015-01-07 | — | — | CN | disclosed |
| EP-2817308-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2013126656-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20130225589-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225589-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | POLB 1112/4885MEN1 1217/4885KMT2A 1407/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | POLB 2872/4885MEN1 4835/4885KMT2A 3685/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | POLB 3437/4885MEN1 4788/4885KMT2A 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.